Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Merritt, K, Perez-Iglesias, R, Sendt, K-V, Goozee, R, Jauhar, S, Pepper, F, Barker, GJ, Glenthøj, B, Arango, C, Lewis, S, Kahn, R, Stone, J, Howes, O, Dazzan, P, McGuire, P & Egerton, A 2019, 'Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate' The Year in Schizophrenia, vol. 5, no. 1, 12, pp. 12. https://doi.org/10.1038/s41537-019-0080-1

APA

Merritt, K., Perez-Iglesias, R., Sendt, K-V., Goozee, R., Jauhar, S., Pepper, F., ... Egerton, A. (2019). Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. The Year in Schizophrenia, 5(1), 12. [12]. https://doi.org/10.1038/s41537-019-0080-1

CBE

Merritt K, Perez-Iglesias R, Sendt K-V, Goozee R, Jauhar S, Pepper F, Barker GJ, Glenthøj B, Arango C, Lewis S, Kahn R, Stone J, Howes O, Dazzan P, McGuire P, Egerton A. 2019. Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. The Year in Schizophrenia. 5(1):12. https://doi.org/10.1038/s41537-019-0080-1

MLA

Vancouver

Author

Merritt, Kate ; Perez-Iglesias, Rocio ; Sendt, Kyra-Verena ; Goozee, Rhianna ; Jauhar, Sameer ; Pepper, Fiona ; Barker, Gareth J ; Glenthøj, Birte ; Arango, Celso ; Lewis, Shôn ; Kahn, René ; Stone, James ; Howes, Oliver ; Dazzan, Paola ; McGuire, Philip ; Egerton, Alice. / Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. In: The Year in Schizophrenia. 2019 ; Vol. 5, No. 1. pp. 12.

Bibtex

@article{cb3673677bd64132b0f0dc4e655b0ba3,
title = "Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate",
abstract = "Neuroimaging studies in schizophrenia have linked elevated glutamate metabolite levels to non-remission following antipsychotic treatment, and also indicate that antipsychotics can reduce glutamate metabolite levels. However, the relationship between symptomatic reduction and change in glutamate during initial antipsychotic treatment is unclear. Here we report proton magnetic resonance spectroscopy (1H-MRS) measurements of Glx and glutamate in the anterior cingulate cortex (ACC) and thalamus in patients with first episode psychosis (n = 23) at clinical presentation, and after 6 weeks and 9 months of treatment with antipsychotic medication. At 9 months, patients were classified into Remission (n = 12) and Non-Remission (n = 11) subgroups. Healthy volunteers (n = 15) were scanned at the same three time-points. In the thalamus, Glx varied over time according to remission status (P = 0.020). This reflected an increase in Glx between 6 weeks and 9 months in the Non-Remission subgroup that was not evident in the Remission subgroup (P = 0.031). In addition, the change in Glx in the thalamus over the 9 months of treatment was positively correlated with the change in the severity of Positive and Negative Syndrome Scale (PANSS) positive, total and general symptoms (P<0.05). There were no significant effects of group or time on glutamate metabolites in the ACC, and no differences between either patient subgroup and healthy volunteers. These data suggest that the nature of the response to antipsychotic medication may be related to the pattern of changes in glutamatergic metabolite levels over the course of treatment. Specifically, longitudinal reductions in thalamic Glx levels following antipsychotic treatment are associated with symptomatic improvement.",
author = "Kate Merritt and Rocio Perez-Iglesias and Kyra-Verena Sendt and Rhianna Goozee and Sameer Jauhar and Fiona Pepper and Barker, {Gareth J} and Birte Glenth{\o}j and Celso Arango and Sh{\^o}n Lewis and Ren{\'e} Kahn and James Stone and Oliver Howes and Paola Dazzan and Philip McGuire and Alice Egerton",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41537-019-0080-1",
language = "English",
volume = "5",
pages = "12",
journal = "The Year in Schizophrenia",
issn = "1477-8122",
publisher = "Clinical Publishing",
number = "1",

}

RIS

TY - JOUR

T1 - Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate

AU - Merritt, Kate

AU - Perez-Iglesias, Rocio

AU - Sendt, Kyra-Verena

AU - Goozee, Rhianna

AU - Jauhar, Sameer

AU - Pepper, Fiona

AU - Barker, Gareth J

AU - Glenthøj, Birte

AU - Arango, Celso

AU - Lewis, Shôn

AU - Kahn, René

AU - Stone, James

AU - Howes, Oliver

AU - Dazzan, Paola

AU - McGuire, Philip

AU - Egerton, Alice

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Neuroimaging studies in schizophrenia have linked elevated glutamate metabolite levels to non-remission following antipsychotic treatment, and also indicate that antipsychotics can reduce glutamate metabolite levels. However, the relationship between symptomatic reduction and change in glutamate during initial antipsychotic treatment is unclear. Here we report proton magnetic resonance spectroscopy (1H-MRS) measurements of Glx and glutamate in the anterior cingulate cortex (ACC) and thalamus in patients with first episode psychosis (n = 23) at clinical presentation, and after 6 weeks and 9 months of treatment with antipsychotic medication. At 9 months, patients were classified into Remission (n = 12) and Non-Remission (n = 11) subgroups. Healthy volunteers (n = 15) were scanned at the same three time-points. In the thalamus, Glx varied over time according to remission status (P = 0.020). This reflected an increase in Glx between 6 weeks and 9 months in the Non-Remission subgroup that was not evident in the Remission subgroup (P = 0.031). In addition, the change in Glx in the thalamus over the 9 months of treatment was positively correlated with the change in the severity of Positive and Negative Syndrome Scale (PANSS) positive, total and general symptoms (P<0.05). There were no significant effects of group or time on glutamate metabolites in the ACC, and no differences between either patient subgroup and healthy volunteers. These data suggest that the nature of the response to antipsychotic medication may be related to the pattern of changes in glutamatergic metabolite levels over the course of treatment. Specifically, longitudinal reductions in thalamic Glx levels following antipsychotic treatment are associated with symptomatic improvement.

AB - Neuroimaging studies in schizophrenia have linked elevated glutamate metabolite levels to non-remission following antipsychotic treatment, and also indicate that antipsychotics can reduce glutamate metabolite levels. However, the relationship between symptomatic reduction and change in glutamate during initial antipsychotic treatment is unclear. Here we report proton magnetic resonance spectroscopy (1H-MRS) measurements of Glx and glutamate in the anterior cingulate cortex (ACC) and thalamus in patients with first episode psychosis (n = 23) at clinical presentation, and after 6 weeks and 9 months of treatment with antipsychotic medication. At 9 months, patients were classified into Remission (n = 12) and Non-Remission (n = 11) subgroups. Healthy volunteers (n = 15) were scanned at the same three time-points. In the thalamus, Glx varied over time according to remission status (P = 0.020). This reflected an increase in Glx between 6 weeks and 9 months in the Non-Remission subgroup that was not evident in the Remission subgroup (P = 0.031). In addition, the change in Glx in the thalamus over the 9 months of treatment was positively correlated with the change in the severity of Positive and Negative Syndrome Scale (PANSS) positive, total and general symptoms (P<0.05). There were no significant effects of group or time on glutamate metabolites in the ACC, and no differences between either patient subgroup and healthy volunteers. These data suggest that the nature of the response to antipsychotic medication may be related to the pattern of changes in glutamatergic metabolite levels over the course of treatment. Specifically, longitudinal reductions in thalamic Glx levels following antipsychotic treatment are associated with symptomatic improvement.

UR - http://www.scopus.com/inward/record.url?scp=85073653431&partnerID=8YFLogxK

U2 - 10.1038/s41537-019-0080-1

DO - 10.1038/s41537-019-0080-1

M3 - Journal article

VL - 5

SP - 12

JO - The Year in Schizophrenia

JF - The Year in Schizophrenia

SN - 1477-8122

IS - 1

M1 - 12

ER -

ID: 58228713